Clinical Trial Update: Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028) [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial update for Doravirine/Islatravir in children under 18 years weighing at least 35 kg with HIV-1; study completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine/Islatravir (doravirine/islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2023-02-24